[SCHEDULE 13G] Theriva Biologics, Inc. SEC Filing

Rhea-AI Filing Summary

Cousins Properties Incorporated (CUZ) has filed an 8-K to report the completion of a major real-estate transaction. On 28 July 2025 the company closed the $218 million acquisition of 2601 Olive Street, “The Link,” a 292,000-sq-ft trophy lifestyle office property located in Uptown Dallas. The news was publicly released on 31 July 2025 through a press release and an investor presentation, which are furnished as Exhibits 99.1 and 99.2.

The filing is strictly a Regulation FD disclosure; it contains no details on financing structure, projected returns, or pro-forma financial impact, and no additional financial statements were required.

Positive

• $218 million acquisition of a 292,000-sq-ft trophy office in Uptown Dallas signals strategic portfolio growth.

Negative

• The 8-K does not disclose financing terms, leverage impact, or projected returns, limiting assessment of the deal’s financial effects.

Insights

Real Estate Analyst

TL;DR: $218 M Dallas trophy office buy broadens CUZ portfolio; likely accretive, but financing details absent.

The purchase of a 292 k sq ft Class-A asset in Uptown Dallas aligns with CUZ’s strategy of owning high-quality Sun Belt office properties. Trophy assets in supply-constrained sub-markets can support higher rents and occupancy, suggesting upside for net operating income once integrated. However, the 8-K omits funding sources and yield targets, limiting visibility on leverage and return metrics. Overall, the transaction appears strategically positive and material in size for CUZ.

Risk Analyst

TL;DR: Material acquisition disclosed; risk profile unclear due to missing financing and ROI data.

While acquiring The Link enhances geographic diversification, the filing offers no insight into debt vs. equity mix, capitalization rate, or lease roll-over, which are critical for assessing balance-sheet risk. Absent these metrics, the immediate credit or liquidity impact cannot be gauged. Investors should review forthcoming quarterly filings or presentations for funding details and any revised guidance.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Theriva Biologics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

87164U508

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Empery Asset Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,185.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,185.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,185.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Includes 482,154 shares of Common Stock issuable upon exercise of the Warrants (as defined in Item 2(a)).

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Ryan M. Lane

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,185.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,185.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,185.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 482,154 shares of Common Stock issuable upon exercise of the Warrants.

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Martin D. Hoe

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,185.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,185.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,185.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 482,154 shares of Common Stock issuable upon exercise of the Warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Theriva Biologics, Inc.
(b)	Address of issuer's principal executive offices: 9605 Medical Center Drive, Suite 270 Rockville, MD 20850
Item 2.
(a)	Name of person filing: This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.001 per share (the "Common Stock") and Common Stock issuable upon exercise of warrants (the "Warrants") of Theriva Biologics, Inc., a Nevada corporation (the "Company"): (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds"); (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, the Empery Funds; and (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, the Empery Funds. The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is: 1 Rockefeller Plaza, Suite 1205 New York, New York 10020
(c)	Citizenship: Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 87164U508
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 9,059,241 shares of Common Stock outstanding as of June 17, 2025, as reported in the Company's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 20, 2025, and assumes exercise of the Warrants (subject to the Blocker (as defined below)). Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the "Blocker"), and the shares of Common Stock listed as beneficially owned in Rows 6, 8 and 9 of the cover page for each Reporting Person and the percentage set forth in Row 11 of the cover page for each Reporting Person give effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blocker. The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such Common Stock.
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a) above.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Empery Asset Management, LP

Signature:	/s/ Ryan M. Lane
Name/Title:	By: Empery AM GP, LLC, its General Partner, By: Ryan M. Lane, its Managing Member
Date:	07/31/2025

Ryan M. Lane

Signature:	/s/ Ryan M. Lane
Name/Title:	Ryan M. Lane, individually
Date:	07/31/2025

Martin D. Hoe

Signature:	/s/ Martin D. Hoe
Name/Title:	Martin D. Hoe, individually
Date:	07/31/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What property did Cousins Properties (CUZ) acquire?

CUZ purchased 2601 Olive Street, known as The Link, a 292,000-sq-ft trophy lifestyle office in Uptown Dallas.

How much did CUZ pay for The Link acquisition?

The purchase price disclosed in the 8-K is $218 million.

When did the The Link transaction close?

The deal closed on July 28, 2025.

Where can investors access additional information about the acquisition?

A press release and investor presentation are furnished as Exhibits 99.1 and 99.2 and posted on CUZ’s website.

Does the filing detail how CUZ financed the purchase?

No. The 8-K does not provide any financing or leverage information for the acquisition.